Arkadios Wealth Advisors Buys New Position in Humana Inc. (NYSE:HUM)

Arkadios Wealth Advisors acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 974 shares of the insurance provider's stock, valued at approximately $258,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Dodge & Cox boosted its stake in shares of Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after buying an additional 5,264,045 shares during the period. Pzena Investment Management LLC raised its holdings in Humana by 6.1% in the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock valued at $1,013,133,000 after acquiring an additional 219,541 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Humana by 11.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,605,771 shares of the insurance provider's stock valued at $407,401,000 after acquiring an additional 160,952 shares during the period. Northern Trust Corp grew its holdings in shares of Humana by 14.5% during the 4th quarter. Northern Trust Corp now owns 1,216,195 shares of the insurance provider's stock worth $308,561,000 after purchasing an additional 153,739 shares in the last quarter. Finally, Sanders Capital LLC increased its position in shares of Humana by 2.3% in the fourth quarter. Sanders Capital LLC now owns 1,194,708 shares of the insurance provider's stock worth $303,109,000 after purchasing an additional 26,367 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Oppenheimer upped their price objective on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Barclays set a $275.00 target price on shares of Humana and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Mizuho increased their price target on shares of Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Bank of America lowered their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research report on Tuesday, June 17th. Finally, Wells Fargo & Company set a $348.00 target price on Humana in a research note on Friday, July 18th. Seventeen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana has an average rating of "Hold" and an average target price of $281.62.

Humana Trading Down 0.3%

Shares of HUM stock traded down $0.66 during mid-day trading on Thursday, reaching $255.96. 850,384 shares of the stock traded hands, compared to its average volume of 2,015,970. The company has a market cap of $30.78 billion, a price-to-earnings ratio of 19.64, a price-to-earnings-growth ratio of 1.51 and a beta of 0.44. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock's fifty day simple moving average is $237.21 and its two-hundred day simple moving average is $254.50. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The firm's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.96 earnings per share. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.